Paul W. Shabram
Directeur Technique/Scientifique/R&D chez BIORA THERAPEUTICS, INC.
Postes actifs de Paul W. Shabram
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BIORA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 25/04/2022 | - |
Historique de carrière de Paul W. Shabram
Anciens postes connus de Paul W. Shabram
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| EMERGENT BIOSOLUTIONS INC. | Directeur Technique/Scientifique/R&D | - | - |
| Ventana Biosciences, Inc. | Fondateur | - | - |
Emergent Travel Health, Inc.
 Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/07/2007 | - |
Formation de Paul W. Shabram
| University of California, Santa Cruz | Undergraduate Degree |
| University of Phoenix | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 7 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Consumer Services | 3 |
| Technology Services | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| EMERGENT BIOSOLUTIONS INC. | Health Technology |
| BIORA THERAPEUTICS, INC. | Health Services |
| Entreprise privées | 2 |
|---|---|
Emergent Travel Health, Inc.
Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Technology Services |
| Ventana Biosciences, Inc. |
- Bourse
- Insiders
- Paul W. Shabram
- Expérience
